Skip to main content
Top
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Origin and distribution of the BRCA2-8765delAG mutation in breast cancer

Authors: Grazia Palomba, Antonio Cossu, Eitan Friedman, Mario Budroni, Antonio Farris, Antonio Contu, Marina Pisano, Paola Baldinu, Maria C Sini, Francesco Tanda, Giuseppe Palmieri

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

The BRCA2-8765delAG mutation was firstly described in breast cancer families from French-Canadian and Jewish-Yemenite populations; it was then reported as a founder mutation in Sardinian families. We evaluated both the prevalence of the BRCA2-8765delAG variant in Sardinia and the putative existence of a common ancestral origin through a haplotype analysis of breast cancer family members carrying such a mutation.

Methods

Eight polymorphic microsatellite markers (D13S1250, centromeric, to D13S267, telomeric) spanning the BRCA2 gene locus were used for the haplotype analysis. Screening for the 8765delAG mutation was performed by PCR-based amplification of BRCA2-exon 20, followed by automated sequencing.

Results

Among families with high recurrence of breast cancer (≥ 3 cases in first-degree relatives), those from North Sardinia shared the same haplotype whereas the families from French Canadian and Jewish-Yemenite populations presented distinct genetic assets at the BRCA2 locus. Screening for the BRCA2-8765delAG variant among unselected and consecutively-collected breast cancer patients originating from the entire Sardinia revealed that such a mutation is present in the northern part of the island only [9/648 (1.4%) among cases from North Sardinia versus 0/493 among cases from South Sardinia].

Conclusion

The BRCA2-8765delAG has an independent origin in geographically and ethnically distinct populations, acting as a founder mutation in North but not in South Sardinia. Since BRCA2-8765delAG occurs within a triplet repeat sequence of AGAGAG, our study further confirmed the existence of a mutational hot-spot at this genomic position (additional genetic factors within each single population might be involved in generating such a mutation).
Appendix
Available only for authorised users
Literature
1.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-89. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998, 62: 676-89. 10.1086/301749.CrossRefPubMedPubMedCentral
3.
go back to reference Szabo C, Masiello A, Ryan JF, The BIC Consortium, Brody LC: The Breast Cancer Information Core: Database Design, Structure, and Scope. Hum Mut. 2000, 16: 123-31. 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y.CrossRefPubMed Szabo C, Masiello A, Ryan JF, The BIC Consortium, Brody LC: The Breast Cancer Information Core: Database Design, Structure, and Scope. Hum Mut. 2000, 16: 123-31. 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y.CrossRefPubMed
4.
go back to reference Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V, Barkardottir RB: Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet. 1996, 58: 749-56.PubMedPubMedCentral Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V, Barkardottir RB: Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet. 1996, 58: 749-56.PubMedPubMedCentral
5.
go back to reference Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998, 352: 1337-9. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet. 1998, 352: 1337-9. 10.1016/S0140-6736(98)03300-5.CrossRefPubMed
6.
go back to reference Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996, 14: 185-7. 10.1038/ng1096-185.CrossRefPubMed Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996, 14: 185-7. 10.1038/ng1096-185.CrossRefPubMed
7.
go back to reference Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi OP: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-15. 10.1093/hmg/6.13.2309.CrossRefPubMed Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi OP: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-15. 10.1093/hmg/6.13.2309.CrossRefPubMed
8.
go back to reference Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998, 63: 1341-51. 10.1086/302099.CrossRefPubMedPubMedCentral Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998, 63: 1341-51. 10.1086/302099.CrossRefPubMedPubMedCentral
9.
go back to reference Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D: The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet. 1998, 63: 272-4. 10.1086/301924.CrossRefPubMedPubMedCentral Lerer I, Wang T, Peretz T, Sagi M, Kaduri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D: The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet. 1998, 63: 272-4. 10.1086/301924.CrossRefPubMedPubMedCentral
10.
go back to reference Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996, 13: 120-2. 10.1038/ng0596-120.CrossRefPubMed Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslehi R, Dion F: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996, 13: 120-2. 10.1038/ng0596-120.CrossRefPubMed
11.
go back to reference Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba MG, Rocca PC, Dedola MF, Olmeo N, Pasca A, Budroni M, Marras V, Pisano A, Farris A, Massarelli G, Pirastu M, Tanda F: Identification of a founder BRCA2 mutation in Sardinia. Brit J Cancer. 2000, 82: 553-9. 10.1054/bjoc.1999.0963.CrossRefPubMedPubMedCentral Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba MG, Rocca PC, Dedola MF, Olmeo N, Pasca A, Budroni M, Marras V, Pisano A, Farris A, Massarelli G, Pirastu M, Tanda F: Identification of a founder BRCA2 mutation in Sardinia. Brit J Cancer. 2000, 82: 553-9. 10.1054/bjoc.1999.0963.CrossRefPubMedPubMedCentral
12.
go back to reference Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F: BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol. 2002, 13: 1899-907. 10.1093/annonc/mdf326.CrossRefPubMed Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F: BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol. 2002, 13: 1899-907. 10.1093/annonc/mdf326.CrossRefPubMed
13.
go back to reference Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G: Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer. 2005, 104: 1172-9. 10.1002/cncr.21298.CrossRefPubMed Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G: Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. Cancer. 2005, 104: 1172-9. 10.1002/cncr.21298.CrossRefPubMed
14.
go back to reference Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson A-M, Foulkes WF, Wang T, Morgan K, Fujiwara TM, Tonin PN: Haplotype analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yeminite Jewish Hereditary Breast Cancer Families. Hum Hered. 2001, 52: 116-20. 10.1159/000053364.CrossRefPubMed Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson A-M, Foulkes WF, Wang T, Morgan K, Fujiwara TM, Tonin PN: Haplotype analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yeminite Jewish Hereditary Breast Cancer Families. Hum Hered. 2001, 52: 116-20. 10.1159/000053364.CrossRefPubMed
17.
go back to reference Meindl A: German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002, 97: 472-80. 10.1002/ijc.1626.CrossRefPubMed Meindl A: German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002, 97: 472-80. 10.1002/ijc.1626.CrossRefPubMed
18.
go back to reference Cortesi L, Turchetti D, Bertoni C, Zanocco-Marani T, Vinceti M, Silvestri C, Federico M, Silingardi V, Ferrari S: Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes. Eur J Hum Genet. 2003, 11: 210-4. 10.1038/sj.ejhg.5200948.CrossRefPubMed Cortesi L, Turchetti D, Bertoni C, Zanocco-Marani T, Vinceti M, Silvestri C, Federico M, Silingardi V, Ferrari S: Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes. Eur J Hum Genet. 2003, 11: 210-4. 10.1038/sj.ejhg.5200948.CrossRefPubMed
19.
go back to reference Wright AF, Carothers AD, Pirastu M: Population choice in mapping genes for complex diseases. Nat Genet. 1999, 23: 397-404. 10.1038/70501.CrossRefPubMed Wright AF, Carothers AD, Pirastu M: Population choice in mapping genes for complex diseases. Nat Genet. 1999, 23: 397-404. 10.1038/70501.CrossRefPubMed
20.
go back to reference Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caraco C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA, Palmieri G: Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer. 2007, 43: 137-43. 10.1016/j.ejca.2006.07.017.CrossRefPubMed Casula M, Colombino M, Satta MP, Cossu A, Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caraco C, Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello G, Ascierto PA, Palmieri G: Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer. 2007, 43: 137-43. 10.1016/j.ejca.2006.07.017.CrossRefPubMed
21.
go back to reference Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996, 2: 1179-83. 10.1038/nm1196-1179.CrossRefPubMed Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JE: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996, 2: 1179-83. 10.1038/nm1196-1179.CrossRefPubMed
22.
go back to reference Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-9. 10.1038/ng0596-117.CrossRefPubMed Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-9. 10.1038/ng0596-117.CrossRefPubMed
23.
go back to reference Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999, 91: 1241-7. 10.1093/jnci/91.14.1241.CrossRefPubMed Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999, 91: 1241-7. 10.1093/jnci/91.14.1241.CrossRefPubMed
24.
go back to reference Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E: Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 2000, 36: 983-6. 10.1016/S0959-8049(00)00045-9.CrossRefPubMed Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E: Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer. Eur J Cancer. 2000, 36: 983-6. 10.1016/S0959-8049(00)00045-9.CrossRefPubMed
25.
go back to reference Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996, 56: 3663-5.PubMed Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, Johannsson OT, Borg A, Ingvarsson S, Easton DF, Egilsson V, Barkardottir RB: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996, 56: 3663-5.PubMed
Metadata
Title
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
Authors
Grazia Palomba
Antonio Cossu
Eitan Friedman
Mario Budroni
Antonio Farris
Antonio Contu
Marina Pisano
Paola Baldinu
Maria C Sini
Francesco Tanda
Giuseppe Palmieri
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-132

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine